Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.63 |
| ▸ | MGLL | Q99685 | 2/20 | 0.63 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12804230 | 0.89 | FAAH (0.76) | FAAHMGLLDRD2DRD3KCNH2 | |
| SCHEMBL381099 | 0.84 | FAAH (0.70) | FAAHMGLLDRD2DRD3KCNH2 | |
| SCHEMBL381031 | 0.80 | ALDH1A1 (0.54) | FAAHMGLLALDH1A1KMT2A | |
| SCHEMBL382462 | 0.76 | FAAH (1.00) | FAAHMGLLDRD2DRD3KCNH2 | |
| SCHEMBL14329550 | 0.76 | ALDH1A1 (0.64) | ALDH1A1KMT2A | |
| SCHEMBL382167 | 0.75 | ALOX5 (0.49) | ALDH1A1KMT2A | |
| SCHEMBL11718771 | 0.75 | ALDH1A1 (0.60) | PTGS2ALDH1A1KMT2A | |
| SCHEMBL10242942 | 0.74 | PTGS2 (0.54) | FAAHMGLLPTGS2 | |
| SCHEMBL31418035 | 0.73 | FAAH (0.57) | FAAHMGLLPTGS2 | |
| SCHEMBL31418152 | 0.72 | FAAH (0.59) | FAAHMGLLPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-10-04 | — | — | US | claimed |
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-10-04 | — | — | US | disclosed |
| EP-2408743-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010105930-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ACHE, CHRNA10, CHRNA5 | FAAH 151/4885MGLL 3954/4885DRD2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.